{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:19:49Z","timestamp":1795025989524,"version":"4.10.2"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,19]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>In the majority of current therapeutic regimens for chronic obstructive pulmonary disease (COPD), bronchodilators are coupled with inhaled corticosteroids (ICS) to lower the inflammatory response and improve symptoms. This study aims to evaluate the safety of ICS in the treatment of COPD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Randomized controlled trials related to ICS for COPD that were eligible up to 1 June 2023 were searched in PubMed, EMBASE, and Cochrane. We searched and screened eligible studies for the occurrence of total adverse events, cardiovascular events, upper respiratory tract infections (URTI), pneumonia, oral Candida infections, and musculoskeletal disorders, and finally analyzed them by Review Manager 5.4.1.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The results showed that ICS increased the incidence of adverse reactions in COPD patients (RR\u2005=\u20051.06, 95% CI: 1.03\u20131.10, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.0004); ICS treatment did not increase the risk of cardiovascular events in COPD patients (RR\u2005=\u20050.95, 95% CI: 0.88\u20131.02, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.14); ICS increased the incidence of URTI in COPD patients (RR\u2005=\u20051.29, 95% CI: 1.02\u20131.62, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.03); ICS increased the incidence of pneumonia in patients with COPD (RR\u2005=\u20052.09, 95% CI: 1.63\u20132.69, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.00001); ICS treatment significantly increased the incidence of oral Candida in patients with COPD (RR\u2005=\u20052.96, 95% CI: 1.99\u20134.41, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.00001); ICS increased the incidence of musculoskeletal disorders in patients with COPD (RR\u2005=\u20052.87, 95% CI: 1.51\u20135.45, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>ICS does not increase the risk of cardiovascular events in patients with COPD, but it does increase the risk of URTI, pneumonia, oral Candida infections, and musculoskeletal disorders in patients with COPD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000036609","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T21:03:04Z","timestamp":1705698184000},"page":"e36609","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Risk of adverse reactions associated with inhaled corticosteroids for chronic obstructive pulmonary disease: A meta-analysis"],"prefix":"10.1097","volume":"103","author":[{"given":"Chenghe","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Cangnan County Hospital of Traditional Chinese Medicine, Wenzhou City, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2985-8081","authenticated-orcid":false,"given":"Xinghua","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Acupuncture, Cangnan County Hospital of Traditional Chinese Medicine, Wenzhou City, Zhejiang Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250505","doi-asserted-by":"crossref","first-page":"1900164","DOI":"10.1183\/13993003.00164-2019","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019.","volume":"53","author":"Singh","year":"2019","journal-title":"Eur Respir J"},{"key":"R2-20250505","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1164\/rccm.202009-3533SO","article-title":"Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease the 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease.","volume":"203","author":"Halpin","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"R3-20250505","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jpainsymman.2020.01.009","article-title":"Chronic obstructive pulmonary disease: a palliative medicine review of the disease, its therapies, and drug interactions.","volume":"60","author":"Weiss","year":"2020","journal-title":"J Pain Symptom Manage"},{"key":"R4-20250505","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/00002018-200225010-00005","article-title":"Benefits and risks of inhaled corticosteroids in chronic obstructive pulmonary disease.","volume":"25","author":"Bonay","year":"2002","journal-title":"Drug Saf"},{"key":"R5-20250505","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1164\/rccm.201701-0218PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report GOLD executive summary.","volume":"195","author":"Vogelmeier","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"R6-20250505","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.chest.2017.07.002","article-title":"Long-term use of inhaled corticosteroids in COPD and the risk of fracture.","volume":"153","author":"Gonzalez","year":"2018","journal-title":"Chest"},{"key":"R7-20250505","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/archinternmed.2008.550","article-title":"Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis.","volume":"169","author":"Singh","year":"2009","journal-title":"Arch Intern Med"},{"key":"R8-20250505","first-page":"CD002991","article-title":"Inhaled corticosteroids for stable chronic obstructive pulmonary disease.","author":"Yang","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"R9-20250505","first-page":"1","article-title":"National ambulatory medical care survey: 2006 summary.","author":"Cherry","year":"2008","journal-title":"Natl Health Stat Rep"},{"key":"R10-20250505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R11-20250505","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1001\/jama.282.7.664","article-title":"Resolving discrepancies between a meta-analysis and a subsequent large controlled trial.","volume":"282","author":"DerSimonian","year":"1999","journal-title":"JAMA"},{"key":"R12-20250505","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1185\/03007995.2015.1036016","article-title":"Efficacy and safety of fluticasone furoate\/vilanterol (50\/25 mcg; 100\/25 mcg; 200\/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial.","volume":"31","author":"Zheng","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"R13-20250505","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.","volume":"387","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"key":"R14-20250505","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/15412550903140881","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50) on COPD exacerbations and impact on patient outcomes.","volume":"6","author":"Anzueto","year":"2009","journal-title":"COPD"},{"key":"R15-20250505","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.rmed.2008.04.019","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50 microg) or salmeterol (50 microg) on COPD exacerbations.","volume":"102","author":"Ferguson","year":"2008","journal-title":"Respir Med"},{"key":"R16-20250505","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1378\/chest.13-0178","article-title":"Efficacy and safety of fluticasone furoate\/vilanterol compared with fluticasone propionate\/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial.","volume":"144","author":"Woodcock","year":"2013","journal-title":"Chest"},{"key":"R17-20250505","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.2112055","article-title":"Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.","volume":"166","author":"Mahler","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R18-20250505","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.","volume":"320","author":"Burge","year":"2000","journal-title":"BMJ"},{"key":"R19-20250505","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.rmed.2011.07.020","article-title":"Effect of budesonide\/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.","volume":"106","author":"Sharafkhaneh","year":"2012","journal-title":"Respir Med"},{"key":"R20-20250505","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/00003495-200969050-00004","article-title":"Efficacy and tolerability of budesonide\/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.","volume":"69","author":"Rennard","year":"2009","journal-title":"Drugs"},{"key":"R21-20250505","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.rmed.2014.05.013","article-title":"Extrafine beclomethasone\/formoterol in severe COPD patients with history of exacerbations.","volume":"108","author":"Wedzicha","year":"2014","journal-title":"Respir Med"},{"key":"R22-20250505","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.rmed.2012.12.014","article-title":"A randomised trial of fluticasone furoate\/vilanterol (50\/25 \u03bcg; 100\/25 \u03bcg) on lung function in COPD.","volume":"107","author":"Kerwin","year":"2013","journal-title":"Respir Med"},{"key":"R23-20250505","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.rmed.2012.12.016","article-title":"Fluticasone furoate\/vilanterol (100\/25; 200\/25 \u03bcg) improves lung function in COPD: a randomised trial.","volume":"107","author":"Martinez","year":"2013","journal-title":"Respir Med"},{"key":"R24-20250505","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/COPD.S27320","article-title":"Effects of mometasone furoate\/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.","volume":"7","author":"Doherty","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"R25-20250505","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1465-9921-9-73","article-title":"One-year treatment with mometasone furoate in chronic obstructive pulmonary disease.","volume":"9","author":"Calverley","year":"2008","journal-title":"Respir Res"},{"key":"R26-20250505","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1136\/thx.2010.136077","article-title":"TORCH Investigators Cardiovascular events in patients with COPD: TORCH study results.","volume":"65","author":"Calverley","year":"2010","journal-title":"Thorax"},{"key":"R27-20250505","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S2213-2600(13)70040-7","article-title":"Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.","volume":"1","author":"Dransfield","year":"2013","journal-title":"Lancet Respir Med"},{"key":"R28-20250505","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.","volume":"146","author":"Aaron","year":"2007","journal-title":"Ann Intern Med"},{"key":"R29-20250505","doi-asserted-by":"crossref","first-page":"1753466619853500","DOI":"10.1177\/1753466619853500","article-title":"The efficacy of adding budesonide\/formoterol to ipratropium plus theophylline in managing severe chronic obstructive pulmonary disease: an open-label, randomized study in China.","volume":"13","author":"Huang","year":"2019","journal-title":"Ther Adv Respir Dis"},{"key":"R30-20250505","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.rmed.2015.04.018","article-title":"Improvements in lung function with umeclidinium\/vilanterol versus fluticasone propionate\/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.","volume":"109","author":"Donohue","year":"2015","journal-title":"Respir Med"},{"key":"R31-20250505","first-page":"73","article-title":"Efficacy and safety characteristics of mometasone furoate\/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.","volume":"7","author":"Tashkin","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"R32-20250505","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(07)61383-X","article-title":"From COPD to chronic systemic inflammatory syndrome?","volume":"370","author":"Fabbri","year":"2007","journal-title":"Lancet"},{"key":"R33-20250505","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.","volume":"187","author":"Vestbo","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"R34-20250505","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/0003-4819-142-4-200502150-00005","article-title":"The effects of a smoking cessation intervention on 145-year mortality: a randomized clinical trial.","volume":"142","author":"Anthonisen","year":"2005","journal-title":"Ann Intern Med"},{"key":"R35-20250505","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1183\/09031936.00128008","article-title":"Systemic manifestations and comorbidities of COPD.","volume":"33","author":"Barnes","year":"2009","journal-title":"Eur Respir J"},{"key":"R36-20250505","first-page":"505","article-title":"Adverse effects of corticosteroids on the cardiovascular system.","volume":"16","author":"Sholter","year":"2000","journal-title":"Can J Cardiol"},{"key":"R37-20250505","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7196\/SAMJ.8716","article-title":"Updated recommendations for the management of upper respiratory tract infections in South Africa.","volume":"105","author":"Brink","year":"2015","journal-title":"S Afr Med J"},{"key":"R38-20250505","doi-asserted-by":"crossref","first-page":"036001","DOI":"10.1088\/1752-7155\/10\/3\/036001","article-title":"Diagnosing viral and bacterial respiratory infections in acute COPD exacerbations by an electronic nose: a pilot study.","volume":"10","author":"van Geffen","year":"2016","journal-title":"J Breath Res"},{"key":"R39-20250505","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12890-020-01315-3","article-title":"Association between inhaled corticosteroids and upper respiratory tract infection in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials.","volume":"20","author":"Chen","year":"2020","journal-title":"BMC Pulm Med"},{"key":"R40-20250505","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1183\/09031936.00095807","article-title":"New evidence of risk factors for community-acquired pneumonia: a population-based study.","volume":"31","author":"Almirall","year":"2008","journal-title":"Eur Respir J"},{"key":"R41-20250505","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/thoraxjnl-2015-206780","article-title":"Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and\/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease.","volume":"70","author":"Torres","year":"2015","journal-title":"Thorax"},{"key":"R42-20250505","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.rmed.2012.04.008","article-title":"The natural history of community-acquired pneumonia in COPD patients: a population database analysis.","volume":"106","author":"M\u00fcllerova","year":"2012","journal-title":"Respir Med"},{"key":"R43-20250505","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1183\/09031936.00193908","article-title":"Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.","volume":"34","author":"Crim","year":"2009","journal-title":"Eur Respir J"},{"key":"R44-20250505","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2008.717","article-title":"Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis.","volume":"300","author":"Drummond","year":"2008","journal-title":"JAMA"},{"key":"R45-20250505","doi-asserted-by":"crossref","first-page":"1800120","DOI":"10.1183\/13993003.00120-2018","article-title":"Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD.","volume":"51","author":"Vedel-Krogh","year":"2018","journal-title":"Eur Respir J"},{"key":"R46-20250505","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1164\/rccm.201701-0193OC","article-title":"Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment data from the FLAME trial.","volume":"195","author":"Roche","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"R47-20250505","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1164\/rccm.200709-1356OC","article-title":"The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease.","volume":"177","author":"Sin","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R48-20250505","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11657-018-0537-2","article-title":"Long-term effects of inhaled corticosteroids on bone mineral density in older women with asthma or COPD: a registry-based cohort study.","volume":"13","author":"Chen","year":"2018","journal-title":"Arch Osteoporos"},{"key":"R49-20250505","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.2147\/COPD.S106054","article-title":"Inhaled corticosteroids can reduce osteoporosis in female patients with COPD.","volume":"11","author":"Liu","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"R50-20250505","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2147\/COPD.S190215","article-title":"Long-term use of inhaled glucocorticoids in patients with stable chronic obstructive pulmonary disease and risk of bone fractures: a narrative review of the literature.","volume":"14","author":"Caramori","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"R51-20250505","doi-asserted-by":"crossref","first-page":"2000515","DOI":"10.1183\/13993003.00515-2020","article-title":"Osteoporosis and fracture risk associated with inhaled corticosteroid use among Swedish COPD patients: the ARCTIC study.","volume":"57","author":"Janson","year":"2021","journal-title":"Eur Respir J"},{"key":"R52-20250505","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s40266-014-0213-1","article-title":"Safety considerations of inhaled corticosteroids in the elderly.","volume":"31","author":"Battaglia","year":"2014","journal-title":"Drugs Aging"},{"key":"R53-20250505","doi-asserted-by":"crossref","first-page":"111","DOI":"10.11005\/jbm.2016.23.3.111","article-title":"Osteoporosis associated with chronic obstructive pulmonary disease.","volume":"23","author":"Okazaki","year":"2016","journal-title":"J Bone Metab"},{"key":"R54-20250505","doi-asserted-by":"crossref","first-page":"1901147","DOI":"10.1183\/13993003.01147-2019","article-title":"Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma.","volume":"55","author":"Maijers","year":"2020","journal-title":"Eur Respir J"},{"key":"R55-20250505","doi-asserted-by":"crossref","first-page":"e024951","DOI":"10.1136\/bmjopen-2018-024951","article-title":"Predicting fracture risk in patients with chronic obstructive pulmonary disease: a UK-based population-based cohort study.","volume":"9","author":"Akyea","year":"2019","journal-title":"BMJ Open"},{"key":"R56-20250505","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jaci.2013.07.038","article-title":"Inhaled long-acting \u03b22 agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPD.","volume":"132","author":"Haque","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"R57-20250505","doi-asserted-by":"crossref","first-page":"65","DOI":"10.11005\/jbm.2019.26.2.65","article-title":"Sarcopenia associated with chronic obstructive pulmonary disease.","volume":"26","author":"Kim","year":"2019","journal-title":"J Bone Metab"},{"key":"R58-20250505","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/COPD.S401736","article-title":"High versus medium dose of inhaled corticosteroid in chronic obstructive lung disease: a systematic review and meta-analysis.","volume":"18","author":"Archontakis Barakakis","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T20:03:43Z","timestamp":1746475423000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036609","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]}}}